Ryan W. Stidham, MD, MSc

Articles by Ryan W. Stidham, MD, MSc

Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts

ByShail M. Govani, MD, MSc,Rachel Lipson, MSc,Mohamed Noureldin, MBBS, MSc,Wyndy Wiitala, PhD,Peter D.R. Higgins, MD, PhD, MSc,Sameer D. Saini, MD, MSc,Jacqueline A. Pugh, MD,Dawn I. Velligan, PhD,Ryan W. Stidham, MD, MSc,Akbar K. Waljee, MD, MSc

December 6th 2018

Veterans with inflammatory bowel disease taking adalimumab appear to be more likely to remain on the drug 1 year after initiation than patients who are privately insured.

Latest Updated Articles

Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts
Published: December 6th 2018 | Updated:

Ryan W. Stidham, MD, MSc

Articles by Ryan W. Stidham, MD, MSc

Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts

Latest Updated Articles

Trending on AJMC

Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review

FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer

Supporting Pharmacy Residents in Completing Research Projects at UC Davis: Jeremiah J. Duby, PharmD, BCPS, BCCCP

Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program

Myasthenia Gravis–Induced Fears of Diagnosed Patients During the Pandemic